Total Payments
$593,858
2024 Payments
$59,896
Companies
58
Transactions
2,763
Medicare Patients
8,159
Medicare Billing
$4.4M
Payment Breakdown by Category
Other$395,829 (66.7%)
Travel$87,508 (14.7%)
Consulting$56,632 (9.5%)
Food & Beverage$49,077 (8.3%)
Research$3,431 (0.6%)
Education$1,381 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $395,829 | 220 | 66.7% |
| Travel and Lodging | $87,508 | 241 | 14.7% |
| Consulting Fee | $56,632 | 21 | 9.5% |
| Food and Beverage | $49,077 | 2,199 | 8.3% |
| Unspecified | $3,431 | 4 | 0.6% |
| Education | $1,381 | 78 | 0.2% |
Payments by Type
General
$590,426
2,759 transactions
Research
$3,431
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $164,848 | 266 | $0 (2019) |
| Lilly USA, LLC | $141,278 | 338 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $62,659 | 125 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $48,667 | 165 | $0 (2024) |
| Amgen Inc. | $45,306 | 263 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $38,049 | 73 | $0 (2019) |
| Kiniksa Pharmaceuticals International, plc | $28,324 | 50 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $14,041 | 35 | $0 (2019) |
| ABBVIE INC. | $12,949 | 318 | $0 (2024) |
| Genentech USA, Inc. | $12,654 | 128 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,896 | 300 | Kiniksa Pharmaceuticals International, plc ($22,092) |
| 2023 | $48,673 | 259 | Lilly USA, LLC ($23,325) |
| 2022 | $58,109 | 318 | Mallinckrodt Hospital Products Inc. ($26,042) |
| 2021 | $27,357 | 253 | Mallinckrodt Hospital Products Inc. ($9,114) |
| 2020 | $44,560 | 314 | Amgen Inc. ($18,010) |
| 2019 | $150,627 | 486 | Celgene Corporation ($47,103) |
| 2018 | $105,572 | 448 | Celgene Corporation ($37,534) |
| 2017 | $99,064 | 385 | Celgene Corporation ($80,211) |
All Payment Transactions
2,763 individual payment records from CMS Open Payments — Page 1 of 111
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: Immunology | ||||||
| 12/18/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $12.39 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | Bioventus LLC | DUROLANE (Device) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: ORTHOPEDICSORTHOPEDIC SURGERY | ||||||
| 12/12/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $8.93 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/11/2024 | SOBI, INC | KINERET (Drug) | Food and Beverage | In-kind items and services | $27.15 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $30.75 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $17.43 | General |
| 12/07/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Rare Disease | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: Immunology | ||||||
| 12/05/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $7.90 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: Bone Health | ||||||
| 12/03/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,275.00 | General |
| Category: Rheumatology | ||||||
| 12/03/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,325.00 | General |
| Category: Rheumatology | ||||||
| 12/03/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $524.08 | General |
| Category: Rheumatology | ||||||
| 12/03/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $361.12 | General |
| Category: Rheumatology | ||||||
| 12/03/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $67.87 | General |
| Category: Rheumatology | ||||||
| 12/03/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $48.44 | General |
| Category: Rheumatology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.66 | General |
| Category: Dermatology | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DS5565-A-E312 | Daiichi Sankyo Inc. | $2,750 | 2 |
| Multiple dose in RA | Boehringer Ingelheim International GmbH | $681.43 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,060 | 35,271 | $3.0M | $951,507 |
| 2022 | 21 | 2,040 | 38,346 | $3.0M | $959,553 |
| 2021 | 24 | 2,333 | 38,435 | $3.0M | $1.0M |
| 2020 | 20 | 1,726 | 56,296 | $3.1M | $1.5M |
Total Patients
8,159
Total Services
168,348
Medicare Billing
$4.4M
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 17 | 4,270 | $814,000 | $258,336 | 31.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 21 | 17,300 | $865,000 | $182,886 | 21.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 95 | 9,480 | $474,000 | $175,108 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 422 | 873 | $208,245 | $96,151 | 46.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 231 | 343 | $109,609 | $54,060 | 49.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 236 | 453 | $73,178 | $36,934 | 50.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 207 | 232 | $92,800 | $36,867 | 39.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 143 | 494 | $79,040 | $35,787 | 45.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 35 | 199 | $72,388 | $25,557 | 35.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 70 | 70 | $31,893 | $13,246 | 41.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 22 | 300 | $22,944 | $8,242 | 35.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 58 | 58 | $21,341 | $8,018 | 37.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 105 | $17,871 | $6,566 | 36.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 126 | 304 | $16,130 | $3,903 | 24.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 19 | 41 | $7,134 | $3,194 | 44.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 242 | 324 | $3,240 | $2,722 | 84.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $4,480 | $1,958 | 43.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 25 | 29 | $2,861 | $1,354 | 47.3% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 23 | 165 | $33,000 | $508.30 | 1.5% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 27 | 215 | $21,500 | $109.30 | 0.5% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 30 | 21,500 | $1.1M | $254,573 | 23.7% |
| J9312 | Injection, rituximab, 10 mg | Office | 2022 | 13 | 3,070 | $614,000 | $205,262 | 33.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 94 | 9,600 | $480,000 | $164,936 | 34.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 451 | 939 | $223,989 | $105,328 | 47.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 263 | 422 | $134,854 | $67,783 | 50.3% |
About Dr. Anna Imperato, M.D
Dr. Anna Imperato, M.D is a Internal Medicine healthcare provider based in Manhasset, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104880780.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anna Imperato, M.D has received a total of $593,858 in payments from pharmaceutical and medical device companies, with $59,896 received in 2024. These payments were reported across 2,763 transactions from 58 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($395,829).
As a Medicare-enrolled provider, Imperato has provided services to 8,159 Medicare beneficiaries, totaling 168,348 services with total Medicare billing of $4.4M. Data is available for 4 years (2020–2023), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Manhasset, NY
- Active Since 04/12/2006
- Last Updated 06/21/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1104880780
Products in Payments
- Otezla (Drug) $200,937
- TALTZ (Drug) $121,262
- ACTHAR (Biological) $100,708
- COSENTYX (Biological) $39,864
- Arcalyst (Drug) $23,291
- KEVZARA SARILUMAB INJECTION (Biological) $13,955
- Actemra (Biological) $11,727
- COSENTYX (Drug) $6,250
- Humira (Biological) $6,225
- Otezla (Biological) $4,797
- TREMFYA (Drug) $4,004
- RINVOQ (Biological) $3,425
- DS-5565 (Drug) $2,750
- KRYSTEXXA (Biological) $2,235
- XELJANZ (Drug) $1,948
- Enbrel (Biological) $1,617
- EVENITY (Biological) $1,148
- Rituxan (Biological) $945.45
- Tymlos (Biological) $932.61
- STELARA (Biological) $927.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Manhasset
Dr. Harmit Kalia, D.o, D.O
Internal Medicine — Payments: $45,969
Internal Medicine $45,969
Bradley Sherman, Md, MD
Internal Medicine — Payments: $31,930
Internal Medicine $31,930
Dr. Samy Selim, Md, MD
Internal Medicine — Payments: $24,755
Internal Medicine $24,755
Emad Sedki, M.d, M.D
Internal Medicine — Payments: $14,573
Internal Medicine $14,573
Suchet Kumar, M.d, M.D
Internal Medicine — Payments: $9,358
Internal Medicine $9,358
Mr. Paul Schwartz, M.d, M.D
Internal Medicine — Payments: $7,084
Internal Medicine $7,084